Title

Analytical cohort study on splenomegaly and cytopenias in myeloproliferative disorders

Authors

Sarvodayai Sinha¹, Vishnu Poovathinkal Rajan², Aditya Unnikrishnan Nair³, Achyuth Prasad Jakka⁴ & Sandhya Palayapadi Chandrasekaran^5,*

Affiliation

¹Department of Critcal Care, Aster Hospital, Muhaisnah, Dubai, UAE; ²Department of General Medicine, ESIC Hospital, Udyogamandal, Ernakulam, Kerala, India; ³Department of General Medicine, Altnagelvin Hospital, Western Health and Social Care Trust, Northern Ireland, UK; ⁴Department of General Medicine, Government Medical College, Anantapuramu andhra Pradesh, India; ⁵Department of General Medicine, Sree Balaji Medical College and Hospital, Chrompet, Chennai, Tamil Nadu, India; *Corresponding author

Email

Sarvodayai Sinha - E-mail: drsarvosinha@gmail.com; Phone: +971 555135565
Vishnu Poovathinkal Rajan - E-mail: ishnupoovathinkal@gmail.com; Phone: +91 8590543089
Aditya Unnikrishnan Nair - E-mail: docadityanair@gmail.com; Phone: +91 7594059089/ +44 7799684858
Achyuth Prasad Jakka - E-mail: achuthachuth2@gmail.com; Phone: +91 8465870029
Sandhya Palayapadi Chandrasekaran - E-mail: sandhyapc.spc@gmail.com; Phone: +91 8754679544

Article Type

Research Article

Date

Received November 15, 2025; Revised December 15, 2025; Accepted December 15, 2025, Published December 15, 2025

Abstract

The relationship between splenomegaly and cytopenias in myeloproliferative disorders (MPDs) remains poorly defined despite its clinical importance. This analytical cohort study evaluated 124 patients with MPDs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, to characterize associations between splenic enlargement and hematologic abnormalities. Splenomegaly was present in 68.5% of patients and showed significant correlations with anemia and thrombocytopenia. Individuals with massive splenomegaly demonstrated greater symptom burden and more pronounced pancytopenia. These findings suggest that splenic size may serve as an important indicator of disease severity and may guide early therapeutic decision-making in MPD management.

Keywords

Myeloproliferative diseases, splenomegaly, hematologic parameters and the severity of the condition

Citation

Sinha et al. Bioinformation 21(12): 4678-4681 (2025)

Edited by

A Prashanth

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.